Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia

European Journal of Internal Medicine

Volumn 14, Issue 6, 2003, Pages 357-360

  Damci, Taner ^a,b   Tatliagac, Serkan ^a   Osar, Zeynep ^a   Ilkova, Kasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Fenofibrate; Glycemic control; Hypertriglyceridemia; Leptin; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FENOFIBRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 11844254843     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(03)90001-X     Document Type: Article

References (17)

1. Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl 2002;3(1):47-51.
2. The Bezafibrate Infarction Prevention (BIP) Study Group, Behar S, Brunner D, Kaplinsky E, Mandelzweig L, Benderly M. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study. Circulation 2000;102:21-7.
3. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357(9260):905-10.
4. Halle M, Berg A, Garwers U, Grathwohl D, Knisel W, Keul J. Concurrent reductions in serum leptin and lipids during weight loss in obese men with type II diabetes. Am J Physiol (Endocrinol Metab) 1999;277(40):E277-82.
5. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes, effects on development and progression. Postgrad Med 2001;109:55-9.
6. Schwartz MW, Woods SC, Porte Jr. D, Seeley RJ, Baskin GD. Central nervous system control of food intake. Nature 2000;404:661-71.
7. Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Kohler C, Fucker K, Julius U. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetolog 2002;39(3):105-10.
8. Ruige JB, Dekkar JM, Blum WF, Stehauwer CDA, Nijpels G, Mooy J, Kostense PJ, Bouter LM, Heine RJ. Leptin and variables of body adiposity, energy balance and insulin resistance in a population based study. The Hoorn Study. Diabetes Care 1999;22:1097-104.
9. Wallace AM, Mc Mahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001;104(25):3052-6.
10. Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T, Ozdemir CI. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001;86:3659-64.
11. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MJ, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002;296(2):293-9.
12. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002;5(5):545-9.
13. Fukushima M, Taniguchi A, Sakai M, Doi K, Nagata I, Nagasaka S, Tokuyama K, Nakai Y. Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000;23(2):259.
14. Ogawa S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, Sato T. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism 2000;49(3):331-4.
15. Klein J, Ott V, Schütt M, Klein HH. Recurrent hypoglycaemic episodes in a patient with type 2 diabetes under fibrate therapy. J Diabetes Complications 2002;16(3):246-8.
16. Whitelaw DC, Smith JM, Nattrass M. Effects of gemfibrosil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridemia. Diabetes Obes Metab 2002;4:187-94.
17. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR_gamma activation. Diabetes 2001;50:411-7.